News Search Results
Jan 11, 2026, 19:00 ET Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 11, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that Dr. Dongxu Shu, Co-Founder, Chairman of the Board, and Chief
More news about: Argo Biopharmaceutical Co., Ltd
Jan 11, 2026, 15:00 ET REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
of the webcast will be available for approximately 30 days following the presentation.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jan 09, 2026, 13:27 ET Ventaris Surgical, Inc. Announces $30M Series A to Advance a Next-Generation System for Complete Kidney Stone Treatment
http://www.ventarissurgical.comAbout Longitude CapitalLongitude Capital is a private investment firm that makes venture growth investments in biotechnology and technology-enabled healthcare companies. The firm has raised over $2.4 billion in capital to-date to help achieve regulatory approvals, scale
More news about: Ventaris Surgical, Inc.
Jan 09, 2026, 10:30 ET Human Microbiome Drugs Market worth $2.13 billion by 2031 | MarketsandMarkets™
others.Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Jan 09, 2026, 10:00 ET Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma: New Results from the eNRGy Trial Presented at ASCO GI
LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announced new data from a post hoc analysis of the eNRGy trial (
More news about: Partner Therapeutics, Inc.
Jan 09, 2026, 08:05 ET Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
employees vesting over four years with a one-year cliff.About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Jan 09, 2026, 08:02 ET iOnctura CEO to present at the 2026 J.P. Morgan Healthcare Conference
Morgan Healthcare Conference is an invite-only event that serves as a vital forum for innovation and capital formation across the pharmaceutical and biotechnology sectors. Participation reflects iOnctura's growing visibility within the global oncology ecosystem and underscores the company's progress towards
More news about: iOnctura
Jan 09, 2026, 08:00 ET Averna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 9, 2026 /PRNewswire/ -- Averna Therapeutics, Inc., a biotechnology company developing novel genomic medicines based on gene insertion technology, today announced that Tom Barnes, Ph.D., Chief Executive Officer,
More news about: Averna Therapeutics
Jan 09, 2026, 08:00 ET Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing
More news about: Curis, Inc.
Jan 09, 2026, 07:30 ET Avista Therapeutics Expands AI Gene Therapy Platform to Break Barriers in the Delivery of Genetic Medicines
avistatx.com) is a biotechnology company spun out of the University of Pittsburgh, and built on deep clinical, computational and gene therapy expertise, whose mission is to break
More news about: Avista Therapeutics
Jan 09, 2026, 07:00 ET Nona Biosciences Enters into Collaboration Agreement with Link Cell Therapies to Advance CAR-T Cell Therapies
CAMBRIDGE, Mass., Jan. 9, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology platforms, today announced that it has entered into a multi-target antibody
More news about: Nona Biosciences
Jan 09, 2026, 06:59 ET Soft Gaskets Market worth $5.56 billion by 2030 - Exclusive Report by MarketsandMarkets™
Hence, envelope gaskets provide the non-reactive, corrosion-resistant, and hygienic sealing surface needed in chemical processing, pharmaceuticals, biotechnology, food & beverage, and high-purity applications. The demand for these gaskets is growing rapidly in Asia, Europe, and North America. The global
More news about: MarketsandMarkets
Jan 08, 2026, 17:06 ET Hong Kong Tech Firms Win Big at CES 2026 with Frontier Tech Innovations to Draw Global Buyer Interest
and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland
More news about: Hong Kong Tech
Jan 08, 2026, 16:05 ET BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
Company's website for a limited time following the conference. About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Jan 08, 2026, 16:00 ET CREATE Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
Mass., Jan. 8, 2026 /PRNewswire/ -- CREATE Medicines, Inc. ("CREATE" or the "Company"), a clinical-stage biotechnology company pioneering in vivo CAR therapy, today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on
More news about: CREATE Medicines, Inc.
Jan 08, 2026, 14:00 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jan 08, 2026, 13:31 ET Akadeum Life Sciences to Highlight How Microbubbles Enable Rapid Cell Therapy Manufacturing for Larger Patient Populations at Biotech Showcase 2026
Level)About Biotech ShowcaseBiotech Showcase is a premier investor and partnering conference that connects private and micro- to mid-cap biotechnology companies with the global investment community and biopharma executives. The annual event provides a forum for emerging innovators to highlight
More news about: Akadeum Life Sciences Inc
Jan 08, 2026, 13:05 ET Muna Therapeutics Awarded $1 Million Alzheimer's Association Grant to Advance Clinical Development of Novel Oral TREM2 Agonist MNA-001 for Alzheimer's
COPENHAGEN, Denmark and BOSTON, Jan. 8, 2026 /PRNewswire/ -- Muna Therapeutics, a clinical-stage biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, today announced it has been awarded a $1 million research
More news about: Muna Therapeutics
Jan 08, 2026, 12:11 ET ELEPHAS BIOSCIENCES STRENGTHENS SCIENTIFIC AND CLINICAL LEADERSHIP AS COMPANY ADVANCES TOWARD COMMERCIAL AVAILABILITY OF ITS LIVE-TUMOR IMMUNOLOGY PLATFORM
to this mission and its proven track record continues to attract industry-leading innovators across oncology and biotechnology.Dr. Patel is a physician-scientist and biotechnology executive with over two decades of leadership experience spanning Genentech, Pfizer, Juno, Lyell, and eFFECTOR Therapeutics.
More news about: Elephas
Jan 08, 2026, 10:30 ET Genomic Biomarkers Market worth $50.31 billion by 2030 | MarketsandMarkets™
https://www.marketsandmarkets.com/requestsampleNew.asp?id=48860286By application, the pharmaceutical & biotechnology companies segment was the fastest-growing segmentPharmaceutical & biotechnology companies were the fastest-growing segment of the genomic biomarkers market by end users. These
More news about: MarketsandMarkets
Jan 08, 2026, 10:20 ET Cleanova Strengthens Filtration Portfolio with Strategic Acquisitions of Airflotek and TES-Clean Air Systems, Entering Ultra-Clean Controlled Environment Markets
cleanroom environments worldwide, serving industries with exceptionally stringent air-quality requirements, including semiconductor manufacturing, biotechnology, and pharmaceuticals. Founded in 1986, TES-Clean Air Systems is the exclusive distributor of Airflotek products and brings decades of cleanroom
More news about: Cleanova
Jan 08, 2026, 10:20 ET Cleanova Strengthens Filtration Portfolio with Strategic Acquisitions of Airflotek and TES-Clean Air Systems, Entering Ultra-Clean Controlled Environment Markets
cleanroom environments worldwide, serving industries with exceptionally stringent air-quality requirements, including semiconductor manufacturing, biotechnology, and pharmaceuticals. Founded in 1986, TES-Clean Air Systems is the exclusive distributor of Airflotek products and brings decades of cleanroom
More news about: Cleanova
Jan 08, 2026, 10:00 ET CORCORAN ANNOUNCES NEW FRANCHISEE IN VIRGINIA WITH LAUNCH OF CORCORAN WILEY
began brokering real estate in 2005, following an extensive career as a Congressional staffer and working as a lobbyist for venture capital and biotechnology industries in both Boston and Washington, D.C. Following his collegiate studies, Justin Wiley honed his skillset through the management and advisory
More news about: The Corcoran Group
Jan 08, 2026, 09:00 ET Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity
TÜBINGEN, Germany, Jan. 8, 2026 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR
More news about: Acousia Therapeutics GmbH
Jan 08, 2026, 08:50 ET Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients
SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical‑stage biotechnology company pioneering autologous regenerative therapies, today announced completion of Cohort Three* dosing in the company's ASPIRO Phase 1/2a trial
More news about: Aspen Neuroscience, Inc.